Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 29, 1999

View Archived Issues

New approach to inhibiting thrombin-induced neuronal cell death

Vagus nerve stimulation offers new possibilities for the treatment of depression

Preliminary results reported for Biojector 2000-delivered malaria vaccine

Biomira's BLP25 liposome technology offers promise as cancer therapy

MGH team identifies TSP-2 as a novel endogenous antiangiogenic factor

Immune Network Research reacquires 1F7 AIDS antibody

Genome Therapeutics initiates osteoporosis genomics alliance with Wyeth-Ayerst

Millennium validates prostate cancer gene target as part of Lilly collaboration

NPS and Allelix finalize merger

Nycomed Amersham files for E.U. approval of ultrasound imaging agent

Schwarz adds new anticonvulsant to R&D portfolio

Impressive early phase II clinical data reported for OvaRex in relapsed ovarian cancer

Cel-Sci completes another study in head and neck cancer

BIM-46068: a pseudopeptide FTase inhibitor with promise for cancer Rx

Interneuron licenses worldwide rights to pagoclone to Warner-Lambert

Salix responds to FDA approvable letter and reacquires rights to UC treatment from AstraZeneca

Agents for accelerating peristalsis in development at Dainippon

New series of selectin inhibitors patented by Sumitomo

Mitsui presents differentiation-inducing agents

ADIR discloses new melatonergic agents with cyclic structure

Antiangiogenic fumagillin analogues in the pipeline at BioChem Pharma

BMS presents new water-soluble triazole antifungal prodrugs with superior properties

Pharmacological profile of SR-141716A, a selective CB1 antagonist, further characterized

Citicoline Stroke Study Group trial does not show benefit for citicoline in overall study population

Aventis receives first product approval: E.U. grants approval of Synercid

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...